Neurimmune and REGENXBIO Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases
Neurimmune is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics for human diseases. Its Reverse Translational Medicine™ platform generates recombinant human monoclonal antibodies with unique therapeutic properties. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy.
Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, fronto-temporal dementia as well cardiomyopathy and type 2 diabetes.
Neurimmune collaborates with Biogen on multiple programs for neurodegenerative diseases and Biogen acquired rights in antibodies BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease. In 2016, Neurimmune partnered with TVM and Eli Lilly’s Chorus unit to advance an antibody for the treatment of amyotrophic lateral sclerosis. In 2017, Neurimmune entered into a collaboration with Ono Pharmaceutical in Japan.